RxDoctor Payments Data

Philip Berman, MD

Cardiovascular Disease · Houston, TXNPI 1891835195

Payments from drug & device makers

$43,508in general payments, 2019–2025

Across 738 payments — averaging $58.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$25K
  • Cvrx, Inc.$3K
  • Johnson & Johnson$2K
  • Novartis$2K
  • Amgen$1K
  • Abbott$1K
  • plus $9K from 41 others

What the payments were for

  • Speaking & faculty fees$22,62552%
  • Travel & lodging$4211%
  • Food & beverage$20,38147%
  • Education$560%
  • Entertainment$260%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$43,508 in reported general payments places this provider in the 85th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$745,865
Medicare patients
1,583
Services billed
5,497

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban379$400,579
XareltoRivaroxaban279$302,355
EntrestoSacubitril/Valsartan137$140,289
FarxigaDapagliflozin Propanediol87$87,289
Repatha SureclickEvolocumab51$51,957
BrilintaTicagrelor39$38,790
JardianceEmpagliflozin14$22,545
VerquvoVericiguat26$21,886
Metoprolol Succinate867$14,190
Repatha SyringeEvolocumab13$13,456
MultaqDronedarone Hcl12$10,930
Rosuvastatin Calcium605$10,901
Ranolazine ErRanolazine64$9,391
Flecainide Acetate134$6,674
Eplerenone45$6,024

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$126$400,579379 claims
Johnson & JohnsonXarelto$2,349$302,355279 claims
NovartisEntresto$1,833$140,289137 claims
AstraZenecaFarxiga, Brilinta$24,745$126,079126 claims
Boehringer IngelheimJardiance$963$22,54514 claims
MerckVerquvo$696$21,88626 claims
Sanofi-aventis U.S. LLCMultaq$239$10,93012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →